ATE454474T1 - Verfahren und kit zur prognose von brustkrebs - Google Patents

Verfahren und kit zur prognose von brustkrebs

Info

Publication number
ATE454474T1
ATE454474T1 AT05763127T AT05763127T ATE454474T1 AT E454474 T1 ATE454474 T1 AT E454474T1 AT 05763127 T AT05763127 T AT 05763127T AT 05763127 T AT05763127 T AT 05763127T AT E454474 T1 ATE454474 T1 AT E454474T1
Authority
AT
Austria
Prior art keywords
breast cancer
prognosis
likelihood
patient
molecular
Prior art date
Application number
AT05763127T
Other languages
English (en)
Inventor
Wen Guo Jiang
Original Assignee
Cardiff Biolog Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0417740A external-priority patent/GB0417740D0/en
Priority claimed from GB0426777A external-priority patent/GB0426777D0/en
Application filed by Cardiff Biolog Ltd filed Critical Cardiff Biolog Ltd
Application granted granted Critical
Publication of ATE454474T1 publication Critical patent/ATE454474T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT05763127T 2004-08-10 2005-07-27 Verfahren und kit zur prognose von brustkrebs ATE454474T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0417740A GB0417740D0 (en) 2004-08-10 2004-08-10 Methods and kit for the prognosis of breast cancer
GB0426777A GB0426777D0 (en) 2004-12-07 2004-12-07 Methods and kit for the prognosis of breast cancer
PCT/GB2005/002971 WO2006016110A1 (en) 2004-08-10 2005-07-27 Methods and kit for the prognosis of breast cancer

Publications (1)

Publication Number Publication Date
ATE454474T1 true ATE454474T1 (de) 2010-01-15

Family

ID=35044601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763127T ATE454474T1 (de) 2004-08-10 2005-07-27 Verfahren und kit zur prognose von brustkrebs

Country Status (14)

Country Link
US (1) US20100035240A1 (de)
EP (1) EP1781814B3 (de)
JP (2) JP5117852B2 (de)
CN (1) CN102443627B (de)
AT (1) ATE454474T1 (de)
AU (1) AU2005271113B2 (de)
CA (1) CA2576113A1 (de)
DE (1) DE602005018789D1 (de)
DK (1) DK1781814T3 (de)
ES (1) ES2339132T7 (de)
GB (1) GB2430741A (de)
MX (1) MX2007001640A (de)
PT (1) PT1781814E (de)
WO (1) WO2006016110A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
CA2664712C (en) * 2006-09-29 2019-07-09 Translational Therapeutics, Inc. Eif4e regulon-based diagnostics
WO2008138868A2 (en) * 2007-05-09 2008-11-20 Traslational Cancer Drugs Pharma, S.L. In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US20100081666A1 (en) * 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
EP2352847B1 (de) 2008-11-10 2014-01-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Gensignatur zur vorhersage der prognose von patienten mit soliden tumoren
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
KR101421326B1 (ko) * 2010-03-30 2014-07-21 서울대학교산학협력단 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
CN103562723B (zh) * 2011-03-27 2017-04-26 欧恩克斯特姆诊断学（毛里求斯）私人有限公司 用于识别肿瘤细胞的标记、方法及其试剂盒
EP2723924A4 (de) * 2011-06-22 2015-03-25 Oncocyte Corp Verfahren und zusammensetzungen zur behandlung und diagnose von krebs
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
JP2015511121A (ja) * 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
CN103235141A (zh) * 2013-04-27 2013-08-07 上海交通大学医学院附属新华医院 Atf3用于预测膀胱癌转移和判断预后的应用
KR101548830B1 (ko) 2013-12-30 2015-08-31 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물
EP3093343B1 (de) * 2014-01-10 2020-01-01 Juntendo Educational Foundation Verfahren zur beurteilung des metastatischen potenzials von lymphknoten von endometriumkrebs
SG11201608358VA (en) * 2014-04-29 2016-11-29 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
CN105986024B (zh) * 2015-02-27 2019-10-25 复旦大学附属肿瘤医院 一组用于三阴性乳腺癌预后的基因及其应用
CN104725488A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 关于紧密连接蛋白抑制剂多肽及其应用
CN104725487A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 紧密连接蛋白抑制剂多肽及其应用
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CN106295244B (zh) * 2015-06-05 2019-09-17 上海交通大学医学院附属瑞金医院 肿瘤诊断标志物的筛选方法、以该方法获得的乳腺癌肺转移相关基因及其应用
EP3321683A4 (de) * 2015-07-09 2018-11-21 Juntendo Educational Foundation Verfahren zur beurteilung des lymphknotenmetastasenpotenzials von endometriumkrebs
CN106337081B (zh) * 2016-02-02 2020-01-21 中国医学科学院肿瘤医院 FABP4基因的SNP位点rs1054135与三阴型乳腺癌预后的相关性
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
EP3364190A1 (de) * 2017-02-20 2018-08-22 Panka Cancer Research AG Verfahren zum nachweis von krebs oder krebszellen
JPWO2018159808A1 (ja) * 2017-03-03 2019-12-26 国立研究開発法人国立がん研究センター 抗ｉｌ−７ｒ抗体の抗体薬物コンジュゲートと、がんまたは炎症を処置することに用いるための、抗ｉｌ−７ｒ抗体と細胞傷害剤との抗体薬物コンジュゲートを含む医薬組成物
CN108504726B (zh) * 2018-03-28 2021-10-26 华南农业大学 采用amf单个孢子微量dna进行pcr预处理的方法
WO2020008097A2 (es) * 2018-07-03 2020-01-09 Universidad De Granada Método de obtención de datos útiles para predecir o pronosticar la supervivencia global y la supervivencia libre de recaídas en el cáncer y composición capaz de modular la actividad de atf4 para el tratamiento del cáncer
CN109620832B (zh) * 2019-01-14 2021-01-01 大连大学 甘氨胆酸在制备抗乳腺增生药物中的应用
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
JP2024521104A (ja) * 2021-05-21 2024-05-28 ウニベルシテ カソリーク デ ルーベン ミトコンドリア標的化抗酸化剤に対する癌の応答性を評価するための分子署名
CN114758773A (zh) * 2022-05-25 2022-07-15 四川大学华西医院 一种膀胱癌免疫治疗生物标志物、免疫风险模型及其应用
CN116656820B (zh) * 2023-05-17 2025-11-18 南华大学附属第一医院 一种基于乳腺肿瘤干细胞相关基因的预后模型及其应用
CN117092336B (zh) * 2023-06-16 2026-06-05 中国医学科学院北京协和医院 血浆n4bp1、creb1、ubap2、deaf1自身抗体标志物在弥漫大b细胞淋巴瘤预后预测中的应用
WO2026015514A1 (en) * 2024-07-11 2026-01-15 The Johns Hopkins University Methods for predicting tumor behavior and metastatic risk in epithelial malignancies
CN118853892B (zh) * 2024-09-29 2024-12-06 四川大学华西医院 一种用于检测乳腺癌的血小板标志物及检测试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
WO1999038500A2 (en) * 1998-01-30 1999-08-05 The Brigham And Women's Hospital, Inc. The human calcium-sensing receptor in the detection and treatment of cancer
JP4892131B2 (ja) * 1998-11-13 2012-03-07 ストライカー コーポレイション 癌の症状を緩和する方法
EP1425302A2 (de) * 2001-01-24 2004-06-09 Protein Design Labs Methoden zur diagnose von brustkrebs sowie methoden zur identifizierung von substanzen, die brustkrebs beeinflussen
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20040086504A1 (en) * 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
AU2002232563A1 (en) * 2001-12-05 2003-06-23 Genzyme Corporation Compounds for therapy and diagnosis and methods for using same
AU2002366712A1 (en) * 2001-12-20 2003-07-09 The Regents Of The University Of California Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure

Also Published As

Publication number Publication date
EP1781814B1 (de) 2010-01-06
JP2012024095A (ja) 2012-02-09
DE602005018789D1 (de) 2011-05-26
CN102443627A (zh) 2012-05-09
JP5117852B2 (ja) 2013-01-16
JP2008508895A (ja) 2008-03-27
GB0701676D0 (en) 2007-03-14
WO2006016110A1 (en) 2006-02-16
AU2005271113B2 (en) 2010-12-09
EP1781814A1 (de) 2007-05-09
AU2005271113A1 (en) 2006-02-16
ES2339132T7 (es) 2012-03-16
PT1781814E (pt) 2010-04-12
HK1103422A1 (en) 2007-12-21
JP5634360B2 (ja) 2014-12-03
WO2006016110A8 (en) 2006-08-24
ES2339132T3 (es) 2010-05-17
MX2007001640A (es) 2007-07-25
CN102443627B (zh) 2014-10-29
GB2430741A (en) 2007-04-04
US20100035240A1 (en) 2010-02-11
CA2576113A1 (en) 2006-02-16
EP1781814B3 (de) 2011-08-31
DK1781814T3 (da) 2010-05-03

Similar Documents

Publication Publication Date Title
DE602005018789D1 (de) Verfahren und kit zur prognose von brustkrebs
Xiao et al. Analysis of the miRNA–mRNA–lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data
Tsai et al. Epigenetic regulation of miR‐34b and miR‐129 expression in gastric cancer
Sarver et al. MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma
UA110790C2 (uk) Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
Liu et al. Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells
Liu et al. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray
ATE498685T1 (de) Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
ATE523786T1 (de) In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens
NZ548655A (en) Predicting bone relapse of breast cancer using markers
Baker et al. Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma
ATE406621T1 (de) Computerimplementiertes verfahren und computergestütztes system zur validierung von dna-sequenzierungsdaten
RU2016131028A (ru) Композиции, содержащие асимметричную интерферирующую рнк, которые подвергают сайленсингу k-ras, и способы их применения
DE60302350D1 (de) Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie
Ashrafi et al. Epigenetics evaluation of the oncogenic mechanisms of two closely related bovine and human deltaretroviruses: A system biology study
Rajski et al. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas
CN113234721A (zh) 结直肠癌细胞中的增强子及其应用
Wen et al. A transcriptome resource for pharaoh cuttlefish (Sepia pharaonis) after ink ejection by brief pressing
ES2544882T3 (es) Determinación del riesgo de metástasis distante en pacientes con cáncer de pulmón de células no pequeñas en estadio I-IIIA, tratados quirúrgicamente
DK1618195T3 (da) Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)
ATE437235T1 (de) Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
Tripathi et al. A preliminary sketch of horn cancer transcriptome in Indian zebu cattle
ATE534654T1 (de) Mit prostatakrebs in zusammenhang stehende zusammensetzungen, verfahren und kits auf grundlage von dna-makroarray-proteom plattformen
Despotović et al. Identifying transcript variants associated with colon cancer: a comparative analysis of 3D spheroid cultures and patient-derived tissues
Mitiushkina et al. Biased detection of guanine-rich microRNAs by array profiling: Systematic error or biological phenomenon?

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1781814

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
UEP Publication of translation of european patent specification

Ref document number: 1781814

Country of ref document: EP